December 19, 2023
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
The Circular is an important legal basis for attracting investment activities and transferring technology for drug production, especially original brand name drugs, patented drugs, specialized drugs, special treatments, and prescription drugs. generic drugs in the form of high-tech dosage forms, vaccines, reference biological products, and similar biological products according to the orientations in the “Program for the development of the domestic pharmaceutical and herbal medicine industry until 2030, with a vision to 2045.” approved by the Prime Minister in Decision No. 376/QD-TTg dated March 17.3.2021, XNUMX.
With the provisions of Circular 16/2023, enterprises that process and transfer drug production technology to Vietnam will be facilitated in carrying out the procedures for registration of drug circulation, shortening the time required for the registration of drug circulation. administrative procedures and processing time for dossiers, and at the same time to consider and apply incentives in participating in bidding for drug supply for medical facilities.
The implementation of the provisions of this circular will also create opportunities for Vietnamese drug manufacturing enterprises to receive advanced and modern drug production processes, technologies and techniques, making the most of their potential. production capacity, while ensuring the initiative in the production and supply of high quality drugs, vaccines and biological products for the medical examination and treatment of the people.
Source: Thanhnien Online
Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: firstname.lastname@example.org | W: www.stellapharm.com
Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.Human studies are the most expensive and time-consuming part of drug development as it can take years to recruit patients and trial
Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use. Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use, aiming
The Ministry of Health is drafting a Circular promulgating a list of drugs, testing supplies, and medical equipment eligible for price negotiation and stipulating the process and procedures for selecting contractors for applicable bidding packages. form of price negotiation. According to the draft, the construction of the drug list is applied in the form of
It is critical for pharmaceutical companies to improve competitiveness with a focus on research and development (R&D), production technology and digitalisation. According to experts, this will help them expand their shares in the domestic market which remains being dominated by imported drugs and extend their international reach.Vietnam’s pharmaceutical market has significant potential. The Ministry of